Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inhibikase Therapeutics (IKT) Shares Issued (2020 - 2025)

Inhibikase Therapeutics (IKT) has disclosed Shares Issued for 6 consecutive years, with $250932.0 as the latest value for Q3 2025.

  • On a quarterly basis, Shares Issued rose 106.95% to $250932.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $103.8 million, a 22955701.11% increase, with the full-year FY2024 number at $103.5 million, up 1111.18% from a year prior.
  • Shares Issued was $250932.0 for Q3 2025 at Inhibikase Therapeutics, up from $31621.0 in the prior quarter.
  • In the past five years, Shares Issued ranged from a high of $103.5 million in Q4 2024 to a low of -$3.6 million in Q3 2024.
  • A 5-year average of $11.8 million and a median of $250932.0 in 2025 define the central range for Shares Issued.
  • Biggest YoY gain for Shares Issued was 22893189.38% in 2024; the steepest drop was 5159035.71% in 2024.
  • Inhibikase Therapeutics' Shares Issued stood at $35357.0 in 2021, then increased by 24.85% to $44142.0 in 2022, then plummeted by 98.98% to $452.0 in 2023, then surged by 22893189.38% to $103.5 million in 2024, then plummeted by 99.76% to $250932.0 in 2025.
  • Per Business Quant, the three most recent readings for IKT's Shares Issued are $250932.0 (Q3 2025), $31621.0 (Q2 2025), and $103.5 million (Q4 2024).